Is INSM or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Scholar Rock N/A -163.52% -96.67%

Is SRRK or VTRS more profitable?

Scholar Rock has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Viatris -2.04% 19.04% 7.62%

Is MRNA or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Scholar Rock N/A -163.52% -96.67%

Is GMAB or SRRK more profitable?

Genmab A/S has a net margin of 21.05% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 21.05% 15.34% 8.94% Scholar Rock N/A -163.52% -96.67%

Scholar Rock (SRRK) Competitors

$44.64 -0.04 (-0.09%)

Closing price 04:00 PM Eastern

Extended Trading

$44.88 +0.24 (+0.54%)

As of 05:45 PM Eastern

Compare

SRRK vs. INSM, ROIV, VTRS, MRNA, and GMAB

Should you buy Scholar Rock stock or one of its competitors? MarketBeat compares Scholar Rock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scholar Rock include Insmed (INSM), Roivant Sciences (ROIV), Viatris (VTRS), Moderna (MRNA), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry.

How does Scholar Rock compare to Insmed?

Insmed (NASDAQ:INSM) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

In the previous week, Insmed had 15 more articles in the media than Scholar Rock. MarketBeat recorded 16 mentions for Insmed and 1 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.87 beat Insmed's score of 1.52 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Overall Sentiment
Insmed	Very Positive
Scholar Rock	Very Positive

Insmed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Scholar Rock has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Scholar Rock	N/A	-163.52%	-96.67%

Scholar Rock has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	37.12	-$1.28B	-$5.75	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

91.1% of Scholar Rock shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 13.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Insmed currently has a consensus target price of $210.95, suggesting a potential upside of 103.11%. Scholar Rock has a consensus target price of $56.00, suggesting a potential upside of 25.45%. Given Insmed's higher probable upside, analysts clearly believe Insmed is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Summary

Scholar Rock beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Roivant Sciences?

Scholar Rock (NASDAQ:SRRK) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Scholar Rock has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Roivant Sciences has higher revenue and earnings than Scholar Rock. Roivant Sciences is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Roivant Sciences	$8.26M	2,499.16	-$299.77M	-$0.60	N/A

In the previous week, Roivant Sciences had 5 more articles in the media than Scholar Rock. MarketBeat recorded 6 mentions for Roivant Sciences and 1 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.87 beat Roivant Sciences' score of 1.42 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Overall Sentiment
Scholar Rock	Very Positive
Roivant Sciences	Positive

Scholar Rock presently has a consensus target price of $56.00, indicating a potential upside of 25.45%. Roivant Sciences has a consensus target price of $33.59, indicating a potential upside of 17.04%. Given Scholar Rock's stronger consensus rating and higher probable upside, equities research analysts plainly believe Scholar Rock is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Scholar Rock has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 13.3% of Scholar Rock shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Scholar Rock beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Viatris?

Scholar Rock (NASDAQ:SRRK) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

In the previous week, Scholar Rock and Scholar Rock both had 1 articles in the media. Viatris' average media sentiment score of 1.89 beat Scholar Rock's score of 1.87 indicating that Viatris is being referred to more favorably in the news media.

Company	Overall Sentiment
Scholar Rock	Very Positive
Viatris	Very Positive

Scholar Rock has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Scholar Rock has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Viatris	-2.04%	19.04%	7.62%

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Scholar Rock currently has a consensus price target of $56.00, indicating a potential upside of 25.45%. Viatris has a consensus price target of $16.43, indicating a potential upside of 5.58%. Given Scholar Rock's stronger consensus rating and higher probable upside, equities research analysts clearly believe Scholar Rock is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Scholar Rock has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Viatris	$14.30B	1.27	-$3.51B	-$0.26	N/A

Summary

Scholar Rock beats Viatris on 9 of the 15 factors compared between the two stocks.

How does Scholar Rock compare to Moderna?

Moderna (NASDAQ:MRNA) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

In the previous week, Moderna had 27 more articles in the media than Scholar Rock. MarketBeat recorded 28 mentions for Moderna and 1 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.87 beat Moderna's score of 0.46 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Overall Sentiment
Moderna	Neutral
Scholar Rock	Very Positive

Scholar Rock has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Scholar Rock	N/A	-163.52%	-96.67%

Moderna currently has a consensus target price of $35.73, indicating a potential downside of 27.16%. Scholar Rock has a consensus target price of $56.00, indicating a potential upside of 25.45%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts clearly believe Scholar Rock is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Scholar Rock has lower revenue, but higher earnings than Moderna. Scholar Rock is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	10.01	-$2.82B	-$8.15	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

75.3% of Moderna shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Summary

Scholar Rock beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Genmab A/S has a net margin of 21.05% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Scholar Rock	N/A	-163.52%	-96.67%

Genmab A/S currently has a consensus price target of $37.93, indicating a potential upside of 58.83%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 25.45%. Given Genmab A/S's higher probable upside, equities research analysts plainly believe Genmab A/S is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.00	$963M	$1.32	18.09
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

In the previous week, Genmab A/S had 3 more articles in the media than Scholar Rock. MarketBeat recorded 4 mentions for Genmab A/S and 1 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.87 beat Genmab A/S's score of 0.58 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Overall Sentiment
Genmab A/S	Positive
Scholar Rock	Very Positive

Genmab A/S has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Summary

Genmab A/S beats Scholar Rock on 10 of the 16 factors compared between the two stocks.

Get Scholar Rock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRRK vs. The Competition

Export

Metric	Scholar Rock	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.35B	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-12.43	9.91	18.89	22.53
Price / Sales	N/A	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	18.52	6.63	9.84	6.72
Net Income	-$377.94M	$24.20M	$3.57B	$337.19M
7 Day Performance	-11.85%	-3.24%	-1.16%	0.48%
1 Month Performance	-3.73%	0.53%	3.85%	5.07%
1 Year Performance	44.28%	47.24%	27.40%	34.25%

Scholar Rock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRRK Scholar Rock	3.3262 of 5 stars	$44.64 -0.1%	$56.00 +25.4%	+50.1%	$5.35B	N/A	N/A	140	Positive News
INSM Insmed	3.7586 of 5 stars	$106.24 flat	$210.95 +98.6%	+44.7%	$23.03B	$606.42M	N/A	1,664	Positive News
ROIV Roivant Sciences	2.8724 of 5 stars	$29.96 flat	$33.05 +10.3%	+152.9%	$21.44B	$8.26M	N/A	860	Positive News
VTRS Viatris	3.227 of 5 stars	$16.65 flat	$16.43 -1.3%	+80.6%	$19.39B	$14.30B	N/A	30,000	Positive News
MRNA Moderna	1.4946 of 5 stars	$46.88 flat	$35.73 -23.8%	+68.7%	$18.60B	$1.94B	N/A	4,700	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRRK) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scholar Rock (SRRK) Competitors

SRRK vs. INSM, ROIV, VTRS, MRNA, and GMAB

How does Scholar Rock compare to Insmed?

Summary

How does Scholar Rock compare to Roivant Sciences?

Summary

How does Scholar Rock compare to Viatris?

Summary

How does Scholar Rock compare to Moderna?

Summary

How does Scholar Rock compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scholar Rock (SRRK) Competitors

SRRK vs. INSM, ROIV, VTRS, MRNA, and GMAB

How does Scholar Rock compare to Insmed?

Does the media prefer INSM or SRRK?

Which has more risk and volatility, INSM or SRRK?

Is INSM or SRRK more profitable?

Which has higher earnings and valuation, INSM or SRRK?

Do institutionals & insiders hold more shares of INSM or SRRK?

Do analysts rate INSM or SRRK?

Summary

How does Scholar Rock compare to Roivant Sciences?

Which has more risk & volatility, SRRK or ROIV?

Which has higher valuation & earnings, SRRK or ROIV?

Does the media refer more to SRRK or ROIV?

Do analysts recommend SRRK or ROIV?

Is SRRK or ROIV more profitable?

Do institutionals & insiders have more ownership in SRRK or ROIV?

Summary

How does Scholar Rock compare to Viatris?

Does the media favor SRRK or VTRS?

Which has more risk & volatility, SRRK or VTRS?

Is SRRK or VTRS more profitable?

Do insiders & institutionals have more ownership in SRRK or VTRS?

Do analysts rate SRRK or VTRS?

Which has preferable earnings & valuation, SRRK or VTRS?

Summary

How does Scholar Rock compare to Moderna?

Does the media favor MRNA or SRRK?

Is MRNA or SRRK more profitable?

Do analysts prefer MRNA or SRRK?

Which has preferable valuation and earnings, MRNA or SRRK?

Do insiders and institutionals believe in MRNA or SRRK?

Which has more volatility and risk, MRNA or SRRK?

Summary

How does Scholar Rock compare to Genmab A/S?

Is GMAB or SRRK more profitable?

Do analysts rate GMAB or SRRK?

Do institutionals and insiders believe in GMAB or SRRK?

Which has stronger valuation and earnings, GMAB or SRRK?

Does the media favor GMAB or SRRK?

Which has more risk & volatility, GMAB or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools